IL298991A - Low-dose pharmaceutical preparations of GHRH analogs and their uses - Google Patents

Low-dose pharmaceutical preparations of GHRH analogs and their uses

Info

Publication number
IL298991A
IL298991A IL298991A IL29899122A IL298991A IL 298991 A IL298991 A IL 298991A IL 298991 A IL298991 A IL 298991A IL 29899122 A IL29899122 A IL 29899122A IL 298991 A IL298991 A IL 298991A
Authority
IL
Israel
Prior art keywords
low
pharmaceutical compositions
dose pharmaceutical
ghrh analogs
ghrh
Prior art date
Application number
IL298991A
Other languages
English (en)
Hebrew (he)
Original Assignee
Theratechnologies Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Theratechnologies Inc filed Critical Theratechnologies Inc
Publication of IL298991A publication Critical patent/IL298991A/en

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22Hormones
    • A61K38/25Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40Cyclodextrins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0019Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/19Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles lyophilised, i.e. freeze-dried, solutions or dispersions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/04Anorexiants; Antiobesity agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00Drugs for disorders of the metabolism
    • A61P3/06Antihyperlipidemics
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575Hormones
    • C07K14/60Growth hormone-releasing factor [GH-RF], i.e. somatoliberin
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Obesity (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Inorganic Chemistry (AREA)
  • Immunology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Genetics & Genomics (AREA)
  • Dermatology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
IL298991A 2020-07-05 2021-06-30 Low-dose pharmaceutical preparations of GHRH analogs and their uses IL298991A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063048167P 2020-07-05 2020-07-05
PCT/CA2021/050904 WO2022006657A1 (en) 2020-07-05 2021-06-30 Low-dose pharmaceutical compositions of ghrh analogs and uses thereof

Publications (1)

Publication Number Publication Date
IL298991A true IL298991A (en) 2023-02-01

Family

ID=79553399

Family Applications (1)

Application Number Title Priority Date Filing Date
IL298991A IL298991A (en) 2020-07-05 2021-06-30 Low-dose pharmaceutical preparations of GHRH analogs and their uses

Country Status (9)

Country Link
US (1) US20230270865A1 (https=)
EP (1) EP4175661A4 (https=)
JP (1) JP2023533498A (https=)
KR (1) KR20230035600A (https=)
CN (1) CN115884783A (https=)
AU (1) AU2021306736A1 (https=)
CA (1) CA3183299A1 (https=)
IL (1) IL298991A (https=)
WO (1) WO2022006657A1 (https=)

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004105789A1 (en) * 2003-05-29 2004-12-09 Theratechnologies Inc. Grf analog compositions and their use
CN101678083A (zh) * 2007-04-04 2010-03-24 瑟瑞技术公司 Ghrh分子的药物制剂
US20100267636A1 (en) * 2009-04-20 2010-10-21 Theratechnologies Inc. Use of cytochrome p450-metabolized drugs and grf molecules in combination therapy
KR20140027284A (ko) * 2011-04-21 2014-03-06 쎄러테크놀로지스 인코포레이티드 성장 호르몬 방출 인자(grf) 유사체 및 이의 용도
US8871713B2 (en) * 2013-03-01 2014-10-28 Theratechnologies Inc. Formulations of growth hormone releasing factor (GRF) molecules with improved stability
US20170037105A1 (en) * 2015-08-03 2017-02-09 Aileron Therapeutics, Inc. Peptidomimetic macrocycles
CA3037757A1 (en) * 2019-03-22 2020-09-22 Theratechnologies Inc. Pharmaceutical compositions of ghrh analogs and uses thereof
US20200297817A1 (en) * 2019-03-22 2020-09-24 Theratechnologies Inc. Pharmaceutical compositions of ghrh analogs and uses thereof
SG11202110469PA (en) * 2019-03-29 2021-10-28 Massachusetts Gen Hospital Ghrh or analogues thereof for use in treatment of hepatic disease

Also Published As

Publication number Publication date
WO2022006657A1 (en) 2022-01-13
KR20230035600A (ko) 2023-03-14
JP2023533498A (ja) 2023-08-03
CN115884783A (zh) 2023-03-31
AU2021306736A1 (en) 2023-01-19
EP4175661A4 (en) 2024-08-07
CA3183299A1 (en) 2022-01-13
US20230270865A1 (en) 2023-08-31
EP4175661A1 (en) 2023-05-10

Similar Documents

Publication Publication Date Title
IL286726A (en) Medical preparations and combinations containing androgen receptor inhibitors and their uses
IL310530A (en) Stabilized compositions of radionuclides and their uses
IL292439A (en) Pharmaceutical preparations of albumin and rapamycin
GB2611642B (en) Pharmaceutical and cosmetic compositions comprising secretomes
PT4153133T (pt) Composições farmacêuticas injetáveis e utilizações das mesmas
IL300090A (en) Pharmaceutical preparations containing VENGLUSTAT
IL311284A (en) Chloride-converted tetralin compounds and pharmaceutical preparations
IL315617A (en) Preparations with improved bioavailability of drugs and their uses
PL3946277T3 (pl) Rozpadające się w jamie ustnej farmaceutyczne kompozycje apiksabanu
IL298991A (en) Low-dose pharmaceutical preparations of GHRH analogs and their uses
EP4380548A4 (en) STABILIZED SOLID ORAL PHARMACEUTICAL COMPOSITION OF VARENICLINE
HK40091688A (en) Low-dose pharmaceutical compositions of ghrh analogs and uses thereof
IL306032A (en) Compositions of SOLABEGRON in micronization and methods of use
DK4126898T3 (en) Budesonide 21-phosphate salts and pharmaceutical compositions containing the same
HUE066812T2 (hu) Az utidelone szilárd, orális készítménye
GB202406893D0 (en) Therapeutic and preventive compositions
IL314046A (en) RIBOCICLIB medicinal preparations
EP4370117A4 (en) PHARMACEUTICAL COMPOSITIONS OF OZANIMOD
GB202003316D0 (en) Pharmaceutical compositions comprising dasatinib anhydrous and uses thereof
GB202019335D0 (en) Pharmaceutical compositions
ES3064824T3 (en) Pharmaceutical formulations of bictegravir and lenacapavir
GB202314361D0 (en) Vaccine compositions and uses thereof
GB202209022D0 (en) Pharmaceutical compositions and formulations for the treatment of retinoblastoma
HUE064547T2 (hu) Gyengén ionizálható vagy nem ionizálható gyógyszerészeti hatóanyagok ön-emulgeáló kompozíciói
HK40100354A (en) Pharmaceutical compositions comprising inhibitors of the androgen receptor and uses thereof